CJC-1295 & Ipamorelin

Why These Two Are Studied Together

UKPWritten & reviewed by The UK Peptides Editorial Team · Research library, UK Peptides2 min readLast reviewed 2026-08-233 cited sources

The short answer

CJC-1295 acts at the GHRH receptor and ipamorelin at the ghrelin receptor, two distinct proteins converging on pituitary GH release. That non-overlap is a real mechanistic rationale for combination, though a rationale is not a demonstrated result.

Key facts

CJC-1295 receptor
GHRHR
Ipamorelin receptor
GHS-R1a
Convergence
Pituitary somatotrophs
Rationale
Independent stimulatory inputs
Usual pairing
Non-DAC form, matching half-lives
Evidence for additivity
Would require a factorial design

The rationale is unusually solid

Most combination arguments in this field assert mechanistic non-overlap without much behind it. Here it is true: GHRHR and GHS-R1a are separate G-protein-coupled receptors with separate endogenous ligands, and both are expressed on pituitary somatotrophs. Two independent inputs to one cell is a textbook setting for additive effects.

Why the non-DAC form is the usual partner

Matching kinetics. Ipamorelin is short-acting, and Modified GRF (1-29) clears in about thirty minutes, so the two produce overlapping brief stimuli. Pairing ipamorelin with the DAC form would combine a transient signal with a continuous one, which is a different experiment and arguably a less coherent one.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

What a rationale is not

It is not evidence of additivity. Establishing that requires a factorial design: each compound alone, both together, and neither, measured on the same endpoint in the same system. Without the single-agent arms there is no way to know whether a combined result exceeds what either produces by itself. REDEFINE 1 did exactly this for CagriSema against its components; no equivalent exists here.

The ceiling both share

Both are secretagogues, so both are limited by what the pituitary has and is willing to release. Somatostatin tone opposes both pathways. Combining two stimulatory inputs does not remove the inhibitory one, and the achievable output remains bounded by the gland rather than by the stimulus.

What is claimed here

Nothing about outcomes. The receptor pharmacology is well characterised and the combination rationale is coherent. Material supplied for laboratory research carries no claim about growth, recovery or body composition in any person.

Frequently asked questions

Why combine a GHRH analogue with a ghrelin receptor agonist?
They act at different receptors converging on the same pituitary cells, which is a real mechanistic rationale rather than an asserted one.
Has the combination been shown to be additive?
That would require a factorial design testing each alone and together. No such study establishes it.
Why the non-DAC form specifically?
Matching kinetics. Both are short-acting, producing overlapping brief stimuli rather than one transient and one continuous signal.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

  • ▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
  • ▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
  • ▸Ghrelin-receptor binding assays for Ipamorelin analogue development
  • ▸Analytical HPLC method development for lipidated GHRH analogues
  • ▸Stability testing under refrigerated storage

Handling checklist

  • ✓Store lyophilised at −20 °C long-term
  • ✓Reconstitute in bacteriostatic water; both peptides dissolve readily
  • ✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
  • ✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
  • ✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Related questions researchers ask

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this contentReport a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.

← Back to Forum